AI assistant
Mirum Pharmaceuticals, Inc. — Director's Dealing 2021
Oct 2, 2021
31228_dirs_2021-10-01_4be29b5b-e447-44e2-874b-e0e3c52370f1.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Mirum Pharmaceuticals, Inc. (MIRM)
CIK: 0001759425
Period of Report: 2021-09-29
Reporting Person: Clements Ian (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-09-29 | Common Stock | A | 9375 | $0.00 | Acquired | 18227 | Direct |
| 2021-10-01 | Common Stock | S | 1574 | $19.256 | Disposed | 16653 | Direct |
Footnotes
F1: The shares became issuable upon the satisfaction of certain performance conditions that were established at the time of the Compensation Committee's approval of a performance-based restricted stock unit award on March 9, 2021. On September 29, 2021, the Compensation Committee certified the achievement of the performance criteria resulting in the vesting of 4,687 shares on September 29, 2021 and 4,688 shares on June 30, 2023.
F2: Shares sold to cover tax withholding obligations associated with the vesting of the performance-based restricted stock unit award granted to the Reporting Person on March 9, 2021.